Laura S. Dominici, MD, of the Dana-Farber Cancer Institute, discusses the lower quality-of-life scores seen after unilateral or bilateral mastectomy compared with breast-conserving surgery in women younger than age 40 who are treated for breast cancer (Abstract GS6-05).
Allison Magnuson, DO, of the University of Rochester Strong Memorial Hospital, discusses the development of a chemotherapy toxicity risk score that is associated with dose reduction as well as reduced respiratory distress and fewer hospitalizations (Abstract GS6-04).
Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Richard G. Gray, MA, MSc, of the University of Oxford, discuss a meta-analysis of individual patient data from 12 randomized trials including 24,912 women on the effects—in terms of recurrence and cause-specific mortality—of prolonging adjuvant aromatase inhibitor therapy beyond 5 years (Abstract GS3-03).
Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute, and Daniel F. Hayes, MD, of the University of Michigan Rogel Cancer Center debate whether all women with breast cancer and positive lymph nodes should receive chemotherapy.
Xavier Pivot, MD, PhD, of the Paul Strauss Cancer Center, discusses final study findings comparing 6 and 12 months of trastuzumab in adjuvant early breast cancer (Abstract GS2-07).
Zaida Morante, MD, of the Instituto Nacional de Enfermedades Neoplasicas, discusses retrospective study findings showing the importance of starting adjuvant chemotherapy for people with triple-negative breast cancer within 30 days of surgery (Abstract GS2-05).
